Citigroup Inc Ultragenyx Pharmaceutical Inc. Call Options Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 12, 2024	BUY	$40.21 - $59.36 $643,360 - $949,760	16,000 New	16,000 $888,000
Q4 2023 Feb 09, 2024	BUY	$31.73 - $49.19 $1.72 Million - $2.67 Million	54,300 Added 268.81%	74,500 $3.56 Million
Q3 2023 Nov 09, 2023	SELL	$34.92 - $46.66 $338,724 - $452,601	-9,700 Reduced 32.44%	20,200 $720,000
Q2 2023 Aug 10, 2023	SELL	$37.35 - $52.15 $933,750 - $1.3 Million	-25,000 Reduced 45.54%	29,900 $1.38 Million
Q1 2023 May 11, 2023	SELL	$36.99 - $48.71 $843,372 - $1.11 Million	-22,800 Reduced 29.34%	54,900 $2.2 Million
Q4 2022 Feb 09, 2023	BUY	$33.72 - $46.33 $2.62 Million - $3.6 Million	77,700 New	77,700 $3.6 Million

325

85.6M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.1B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.